{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"425"}],"units":"Participants"}],"groups":[{"description":"Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \\[doxorubicin\\], Oncovin \\[vincristine\\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.","id":"OG000","title":"Rituximab 375 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat (ITT) population: All patients who received at least 1 dose of rituximab regardless of infusion rate.","reportingStatus":"POSTED","timeFrame":"Cycle 1","title":"Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 1","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}